Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling

Ixazomib is an oral proteasome inhibitor, approved in USA, Canada, Australia and Europe in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy. We report a population pharmacokinetic model-based analysis fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Neeraj, Diderichsen, Paul M., Hanley, Michael J., Berg, Deborah, van de Velde, Helgi, Harvey, R. Donald, Venkatakrishnan, Karthik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648746/
https://www.ncbi.nlm.nih.gov/pubmed/28290121
http://dx.doi.org/10.1007/s40262-017-0526-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648746/
https://www.ncbi.nlm.nih.gov/pubmed/28290121
http://dx.doi.org/10.1007/s40262-017-0526-4

Ejemplares similares